Cyclacel Pharmaceuticals Inc Stock Nasdaq
Equities
US23254L3069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.03M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.17
x | P/E ratio 2025 * |
-0.09
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.05% |
Latest transcript on Cyclacel Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-12-31 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 06-02-28 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
1st Jan change | Capi. | |
---|---|---|
-2.12% | 104B | |
+1.62% | 97.42B | |
+0.79% | 22.2B | |
-17.76% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.11% | 15.06B | |
+3.53% | 13.98B | |
+33.26% | 11.66B |